Aegerion Pharmaceuticals Inc. (AEGR) announced after the close Tuesday that JUXTAPID has been approved by Japan's Ministry of Health, Labor & Welfare for the treatment of homozygous familial hypercholesterolemia. The stock is now up …
Aegerion did not reveal the terms of the offering in the filing, but said it had applied to list its stock on Nasdaq under the symbol “AEGR.” AEGR.O Our Standards:The Thomson Reuters Trust Principles.
Wall Street ratings agencies set the tone for today's stock market. Aegerion Pharmaceuticals (AEGR): Shares are up ahead of this morning's opening bell after Leerink Swann took its price target up by $5, to $30. JPMorgan is also …
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that …
On the timing of the event, they quip "Hopefully after bonus time." Commenting on the stock impact should this event come true, they said: Biotech valuations have benefited from an optimistic or “glass half full” view toward clinical data for some …
Aegerion Pharmaceuticals, Inc. AEGR announced its plans to reduce its global workforce ... Aegerion is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF, Anika Therapeutics Inc. …
Aegerion Pharmaceuticals, Inc. AEGR announced that it has entered into a definitive ... Post completion, each outstanding share of Aegerion’s common stock will be exchanged for 1.0256 shares of QLT’s common stock. QLT will change its …